All In Biotech

Drug Trial Radar · NCT06647550

To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Dec 12, 2024

Primary completion

Mar 31, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Hyundai PharmIndustry
Sponsor type
Industry
First posted
Oct 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • HD-6277 100mgDrug

    PO, QD

  • HD-6277 50mgDrug

    PO, QD

  • HD-6277 25mgDrug

    PO, QD

  • PlaceboDrug

    PO, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in HbA1c at weeks 12 from baselineTime frame: at weeks 12 from baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.